Note how much WAS NOT disclosed
AMRAD Recommendation change
AMRAD has struck a licensing deal with the Australian subsidiary of US pharmaceutical company Merck Sharp & Dohme. AMRAD has received an upfront payment of US$5m with the potential for further milestone payments and future royalties.
The actual technology at the centre of the deal was not disclosed. It stems from research conducted by AMRAD and partners, that is based on a "target" for which drugs are developed to act upon. At this stage, the most advanced therapeutic area is for the treatment of asthma and the deal would ideally lead to the development of drugs for this indication.
Additional areas that may deliver drug candidates include other respiratory diseases and oncology (anti-cancer compounds). AMRAD has valued the best outcome from the deal at US$112m plus royalties. However, to achieve this, the technology would need to deliver a human health product for all indications (i.e. not just asthma).
Actual indications were not disclosed nor was the timeframe.
It would be fair to say that the commercialisation of a product would take up to ten years. Hence the reality is, it will be a long road to achieve the full potential of this deal but there will be shorter-term milestone payments available.
We have upgraded our short term recommendation to Hold. Although the size and timing of future payments from this deal are unclear, the upfront US$5m is a positive sign for AMRAD’s technology. We highlight that the stock remains speculative due to the early stage pipeline and uncertainty of future cashflows.
- Forums
- ASX - By Stock
- AML
- macca's view - it'll be a long wait
macca's view - it'll be a long wait
Featured News
Add AML (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.578M |
Open | High | Low | Value | Volume |
0.6¢ | 0.6¢ | 0.6¢ | $3.492K | 582K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 6346119 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 505002 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
29 | 6346119 | 0.005 |
8 | 5873256 | 0.004 |
3 | 1900000 | 0.003 |
1 | 500000 | 0.002 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 505002 | 3 |
0.007 | 1556364 | 4 |
0.008 | 1319052 | 5 |
0.009 | 55600 | 1 |
0.010 | 286667 | 2 |
Last trade - 14.18pm 29/03/2024 (20 minute delay) ? |
Featured News
AML (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online